Eisai (OTCMKTS:ESALY) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Eisai (OTCMKTS:ESALY) from a hold rating to a strong-buy rating in a research note issued to investors on Tuesday, Zacks.com reports. They currently have $58.00 price target on the stock.

According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “

Separately, Citigroup raised shares of Eisai from a sell rating to a neutral rating in a research report on Monday, August 5th.

Shares of Eisai stock opened at $50.42 on Tuesday. The firm has a 50-day moving average of $53.39 and a 200-day moving average of $62.01. The stock has a market cap of $14.41 billion, a PE ratio of 25.30, a PEG ratio of 2.13 and a beta of 0.24. Eisai has a 52-week low of $49.89 and a 52-week high of $101.80. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.66 and a current ratio of 1.90.

About Eisai

Eisai Co, Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It develops Fycompa, an antiepileptic drug in the neurology area that is approved as an adjunctive therapy for partial-onset seizures in Japan, the United States, Europe, and Asia. The company is also approved for use as monotherapy for the treatment of partial onset seizures in the United States; and as an adjunctive therapy for primary generalized tonic-clonic seizures in Japan, the United States, Europe, and Asia.

Further Reading: CD Ladder

Get a free copy of the Zacks research report on Eisai (ESALY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.